Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, … Read more
Oryzon Genomics S.A - Asset Resilience Ratio
Oryzon Genomics S.A (ORYZF) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2020)
This chart shows how Oryzon Genomics S.A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Oryzon Genomics S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-2.84K | -0.0% |
| Total Liquid Assets | $-2.84K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Oryzon Genomics S.A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Oryzon Genomics S.A Industry Peers by Asset Resilience Ratio
Compare Oryzon Genomics S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Oryzon Genomics S.A (2014–2020)
The table below shows the annual Asset Resilience Ratio data for Oryzon Genomics S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | -0.04% | $-40.50K | $94.11 Million | -0.22pp |
| 2019-12-31 | 0.18% | $141.56K | $80.09 Million | -0.03pp |
| 2018-12-31 | 0.21% | $141.56K | $67.45 Million | -0.14pp |
| 2017-12-31 | 0.35% | $213.18K | $61.04 Million | +0.35pp |
| 2016-12-31 | 0.00% | $148.72 | $49.74 Million | -5.98pp |
| 2015-12-31 | 5.98% | $2.44 Million | $40.73 Million | +6.22pp |
| 2014-12-31 | -0.24% | $-63.23K | $26.06 Million | -- |